Sponsor
1 Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial The Lancet, May 16, 2013
2 A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (coral) study European Urology, May 2, 2013
3 Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A Quebec Societal Perspective Spine, May 13, 2013 Evidence Based Medicine
4 Back Pain in Adults Primary Care: Clinics in Office Practice, May 16, 2013 Review Article
5 A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: The PrOP study Journal of Bone and Mineral Research, May 10, 2013
6 The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial Annals of Rheumatic Diseases, May 7, 2013
7 Osteosarcoma of the mobile spine Annals of Oncology, April 25, 2013
8 Prescription Opioids for Back Pain and Use of Medications for Erectile Dysfunction Spine, May 13, 2013 Evidence Based Medicine
9 Effectiveness of an 8-week exercise programme on pain and specificity of neck muscle activity in patients with chronic neck pain: A randomized controlled study European Journal of Pain, May 8, 2013
10 Dual-energy X-ray absorptiometry versus quantitative ultrasonography in diagnosing osteoporosis in patients with refractory epilepsy and chronic antiepileptic drug use Therapeutic Advances in Musculoskeletal Disease, May 2, 2013
Sponsor
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor